Status:

COMPLETED

Biological Efficacy of Clopidogrel After Implantation of Drug-eluting Stents (SPACE)

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Collaborating Sponsors:

Sanofi

Conditions:

Coronary Artery Disease

Atherosclerosis

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The risk of thrombotic complications after implantation of drug-eluting stents (DES) may be increased in patients with diabetes mellitus (DM) or metabolic syndrome (MS). It is recommended that all pat...

Detailed Description

The risk of thrombotic complications after implantation of drug-eluting stents (DES) in coronary arteries may be increased in patients with diabetes mellitus (DM) or metabolic syndrome (MS). It is rec...

Eligibility Criteria

Inclusion

  • Age ≥18 years
  • Documented myocardial ischaemia (stable angina with positive stress ECG or stress myocardial scintigraphy, silent ischemia with positive stress ECG or stress myocardial scintigraphy, non-ST elevation acute coronary syndrome)
  • Treatment with at least 100 mg/day of aspirin for ≥ 6 hours before percutaneous coronary intervention
  • 600 mg clopidogrel loading-dose given ≥ 6 hours and \< 24 hours before coronary angiography
  • Presence of one or several stenosis in native coronary arteries requiring percutaneous coronary intervention and implantation of one or several drug-eluting stents

Exclusion

  • ST-elevation acute coronary syndrome
  • Pregnancy or breast feeding
  • Severe disease with life expectancy lower than 1 year
  • High bleeding risk (blood coagulation disorders, uncontrolled severe hypertension, active bleeding, history of severe bleeding)
  • Intolerance or contraindication to aspirin or clopidogrel
  • Current treatment (or stopped \< 10 days) with vitamin K antagonist
  • Current treatment (or stopped \< 10 days) with clopidogrel (except for the clopidogrel loading-dose given prior to percutaneous coronary intervention), ticlopidine, dipyridamole, non-steroidal antiinflammatory agent, GPIIB-IIIA blocker
  • One-year follow-up impossible
  • Refusal to sign the information and consent form

Key Trial Info

Start Date :

May 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2008

Estimated Enrollment :

159 Patients enrolled

Trial Details

Trial ID

NCT00298428

Start Date

May 1 2006

End Date

December 1 2008

Last Update

September 26 2011

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Département de Cardiologie, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris

Paris, France, 75018

2

Service d'Hématologie et d'Immunologie Biologiques, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris

Paris, France, 75018